AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 283 min read$KIDS

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 7:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$KIDSNeutralMed
01

Why it matters

The earnings call provides fresh quantitative guidance, influencing valuation models and short-term price action.

02

Market read

New earnings and guidance data create a trading opportunity for KIDS, with potential upside if market digests improved revenue outlook.

03

What to watch

Potential regulatory delays for ELI implant and reliance on limited-launch products could delay profitability improvements.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

OrthoPediatrics reported Q3 results with record revenue, margin details, and forward guidance for Q4, highlighting product launch timelines and international growth constraints.

Company-level read

Ticker impact

$KIDSNeutralHigh confidence
Context

Q3 earnings call disclosed record revenue, GAAP loss per share of $0.25 and raised Q4 guidance to $69M, providing fresh guidance and margin details.

Expected impact

likely modest upside as market prices in higher Q4 revenue guidance, though pressure may arise from ongoing loss and expense growth

Evidence & confidence

New guidance and margin numbers are primary disclosure; investors will reassess valuation based on improved revenue outlook and margin guidance.

Market effects

Sector

Positive signal for pediatric orthopedics sector as supercycle product launches progress, may lift peers with similar product pipelines.

Regional

U.S. focused; limited immediate impact on international markets.

Global

Low; relevance confined to niche medical device investors.

Counterpoint

What could challenge this read

Despite raised guidance, continued GAAP losses and high sales/marketing spend could pressure the stock if revenue growth stalls.

Key entities

  • Executive
    David Bailey

    CEO of OrthoPediatrics, provided commentary on product launches and guidance.

  • Executive
    Fred Hite

    CFO of OrthoPediatrics, discussed margin and expense dynamics.

Read at source← All news

Also covered by

2 outlets

Related articles

OCT 28
$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

finance.yahoo.com2 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com3 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics receives FDA clearance for femur nail system

OrthoPediatrics (KIDS) received FDA clearance for its Pediatric Nailing Platform Femur Retrograde Nail System, designed for pediatric trauma and deformity correction. The system is available in diameters from 7 mm to 11 mm and will be released in 2026, with broader commercialization in 2027. The company has used its Pediatric Nailing Platform in approximately 15,000 patients worldwide.

investing.com2 min
OCT 27
$KIDSHigh

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million…

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:

SEC EDGAR 8-K2 min
SEP 11
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, up 15% YoY, and raised 2026 guidance to $265M-$269M. Trauma and Deformity revenue grew 26%, while international sales rose 22%. Despite higher expenses, gross margin expanded to 74% and adjusted EBITDA doubled to $6.8M. Net loss remained at $7.2M, and cash reserves declined to $47.9M.

insidermonkey.com2 min